Use of depot antipsychotics in Belgium between 1997 and 2016
BACKGROUND: Antipsychotics are considered the cornerstone for the treatment of schizophrenia and are increasingly used in the treatment of mood disorders. A lack of drug adherence is a frequently occurring problem. Depot antipsychotics have been co-developed in order to deal with this problem.
AIM: To map the depot antipsychotics prescription behaviour of psychiatrists and general practitioners in outpatient practice in Belgium.
METHOD: Analysis of sales data of antipsychotics between 1997 and 2016. Data were supplied by Pharmanet, a database within the National Institute for Health and Disability Insurance (NIHDI).
RESULTS: In the period 1997-2004, outpatient sales of depot antipsychotics decreased by 20%. The portion of depot antipsychotics in total antipsychotics sales dropped from 14.9% (1997) to 8.5% (2004). After second-generation depot antipsychotics were introduced from 2004, the sales figures of depot antipsychotics increased by 83%. In 2016, 9.8% of antipsychotic prescriptions was a depot antipsychotic prescription. As of 2012, more second-generation depot antipsychotics (52.2%) were sold than first-generation depot antipsychotics (47.8%). Psychiatrists were quicker to adopt second-generation depot antipsychotics than general practitioners, a trend similar to oral antipsychotics.
CONCLUSION: Outpatient sales of depot antipsychotics in Belgium were on the rise after second-generation long-acting preparations were introduced to the market. Recent Scandinavian studies suggest that an increase in prescription of depot antipsychotics may contribute to better clinical outcomes.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Tijdschrift voor psychiatrie - 63(2021), 9 vom: 13., Seite 630-637 |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Gebruik van depotantipsychotica in België, 1997-2016 |
|---|
| Beteiligte Personen: |
Tielens, S [VerfasserIn] |
|---|
| Themen: |
Antipsychotic Agents |
|---|
| Anmerkungen: |
Date Completed 15.10.2021 Date Revised 15.10.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM331880431 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331880431 | ||
| 003 | DE-627 | ||
| 005 | 20231225214439.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331880431 | ||
| 035 | |a (NLM)34647300 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Tielens, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of depot antipsychotics in Belgium between 1997 and 2016 |
| 246 | 3 | 3 | |a Gebruik van depotantipsychotica in België, 1997-2016 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2021 | ||
| 500 | |a Date Revised 15.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Antipsychotics are considered the cornerstone for the treatment of schizophrenia and are increasingly used in the treatment of mood disorders. A lack of drug adherence is a frequently occurring problem. Depot antipsychotics have been co-developed in order to deal with this problem | ||
| 520 | |a AIM: To map the depot antipsychotics prescription behaviour of psychiatrists and general practitioners in outpatient practice in Belgium | ||
| 520 | |a METHOD: Analysis of sales data of antipsychotics between 1997 and 2016. Data were supplied by Pharmanet, a database within the National Institute for Health and Disability Insurance (NIHDI) | ||
| 520 | |a RESULTS: In the period 1997-2004, outpatient sales of depot antipsychotics decreased by 20%. The portion of depot antipsychotics in total antipsychotics sales dropped from 14.9% (1997) to 8.5% (2004). After second-generation depot antipsychotics were introduced from 2004, the sales figures of depot antipsychotics increased by 83%. In 2016, 9.8% of antipsychotic prescriptions was a depot antipsychotic prescription. As of 2012, more second-generation depot antipsychotics (52.2%) were sold than first-generation depot antipsychotics (47.8%). Psychiatrists were quicker to adopt second-generation depot antipsychotics than general practitioners, a trend similar to oral antipsychotics | ||
| 520 | |a CONCLUSION: Outpatient sales of depot antipsychotics in Belgium were on the rise after second-generation long-acting preparations were introduced to the market. Recent Scandinavian studies suggest that an increase in prescription of depot antipsychotics may contribute to better clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 700 | 1 | |a Destoop, M |e verfasserin |4 aut | |
| 700 | 1 | |a Morrens, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tijdschrift voor psychiatrie |d 2006 |g 63(2021), 9 vom: 13., Seite 630-637 |w (DE-627)NLM165211156 |x 0303-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2021 |g number:9 |g day:13 |g pages:630-637 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2021 |e 9 |b 13 |h 630-637 | ||